Anti-virus agent and method for treatment of viral infection

Abstract

A method of treatment of viral infection in a subject comprising administering to the subject a copolymer comprising an acrolein derived segment or a polyacrolein oligomer segment and a polyalkylene glycol oligomer segment, the copolymer having a molecular weight of no more than 1500 Daltons.

1 .- 30 . (canceled) 
     
     
         31 . A method of treatment of a parenteral viral infection in a subject comprising administering to the subject a copolymer comprising an acrolein-derived segment and a polyalkylene glycol oligomer segment, the copolymer having a molecular weight of no more than 1000 Daltons. 
     
     
         32 . The method according to  claim 31 , wherein the acrolein-derived segment is a polyacrolein oligomer comprising two or more acrolein residues. 
     
     
         33 . The method according to  claim 31 , wherein the copolymer has a molecular weight of from 300 to 1000 Daltons. 
     
     
         34 . The method according to  claim 31 , wherein the polyalkylene glycol oligomer segment has a molecular weight in the range of from 200 to 600 Daltons. 
     
     
         35 . The method according to  claim 31 , wherein the polyalkylene glycol oligomer segment has a molecular weight in the range of from 200 to 400 Daltons. 
     
     
         36 . The method according to  claim 31 , wherein a polyalkylene glycol of the polyalkylene glycol oligomer segment is polyethylene glycol. 
     
     
         37 . The method according to  claim 31 , wherein the copolymer has a molecular weight of from 400 to 800 Daltons. 
     
     
         38 . The method according to  claim 31 , wherein the copolymer is administered systemically. 
     
     
         39 . The method according to  claim 31 , wherein the copolymer is administered by a route selected from the group consisting of oral administration, inhalation, transdermal delivery and injection. 
     
     
         40 . The method according to  claim 31 , wherein the copolymer is administered by oral administration. 
     
     
         41 . The method according to  claim 31 , wherein the copolymer is administered by intravenous injection or infusion. 
     
     
         42 . The method according to  claim 31 , wherein the copolymer is administered as an aqueous solution comprising a copolymer concentration in the range of from 0.01% by weight to 20% by weight of the aqueous solution. 
     
     
         43 . The method according to  claim 31 , wherein the copolymer is administered orally in the form of a tablet, caplet, syrup or liquid. 
     
     
         44 . The method according to  claim 31 , wherein the copolymer is administered systemically at a dose in the range of from 1 mg to 1000 mg per kilogram of bodyweight per day. 
     
     
         45 . The method according to  claim 31 , wherein the parenteral viral infection is selected from the group consisting of a influenza viral infection, an HIV infection, a hepatitis viral infection, a Ross River viral infection, and a herpes viral infection. 
     
     
         46 . The method according to  claim 31 , wherein the parenteral viral infection is an influenza viral infection. 
     
     
         47 . A process of preparing a copolymer comprising an acrolein-derived segment and a polyalkylene glycol oligomer comprising:
 adding a first aqueous solution comprising an acrolein having an acrolein concentration of no more than 50% w/w by weight of the first aqueous solution to a second aqueous solution comprising polyethylene glycol and at least 10% w/w water by weight of the second aqueous solution; thereby forming a third aqueous solution; and   polymerizing the acrolein under conditions of alkaline catalysis at a pH no more than 12 in the third aqueous solution, and thereby forming a copolymer, wherein:   the molecular weight of the polyalkylene glycol is from 200 to 600 Daltons and the copolymer has a molecular weight of no more than 1000 Daltons;   the second aqueous solution has a pH of no more than 12.0;   the third aqueous solution comprises at least 20% w/w water by weight of the third aqueous solution; and   the copolymer has a weight ratio of polyalkylene glycol:acrolein of at least 4:1.   
     
     
         48 . The process according to  claim 47 , wherein the second aqueous solution has a pH of from 9 to 11. 
     
     
         49 . The process according to  claim 47 , wherein:
 the second aqueous solution is a mildly basic aqueous solution having a pH of no more than 12.0;   the polyalkylene glycol has a molecular weight in the range of from 200 to 600 Daltons;   the mildly basic solution is stirred vigorously to entrain air;   the first aqueous solution is added over a period of at least 2 minutes the polymerization temperature is maintained in the range of from 10° C. to 40° C.; and   acid is added to provide a pH less than 9 once the acrolein has been consumed.   
     
     
         50 . A copolymer effective in treatment of parenteral viral infection in a subject by systemic administration, the copolymer comprising an acrolein-derived segment and a polyalkylene glycol oligomer segment wherein:
 the copolymer has a molecular weight of no more than 1000 Daltons; and   the polyalkylene glycol oligomer segment has a molecular weight in the range of 200 to 600 Daltons.